สรุปข้อมูลกองทุน Fund Summary

Date 29 February 2024

SCB Genomic Revolution (Accumulation) SCBGENOME(A)



Deposit 1.36%

Derivative -1.48% Other 4.51%

ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF 23.13%



Fund Summary

Fund Type

Fund Registration date

Investment Policy

Foreign Investment Fund

at least 2 foreign mutual funds that focus on investing in securities/instruments of companies related to the Genomic Revolution Theme, which focuses on and expected to benefit from quality development of human life through development and progress in technology and science, on average, in an accounting year of not less than 80% of the Fund's NAV.

Net Asset Value

Net Asset Value Per Unit

Policy on Dividend Payment

Automatic redemption policy

Risk Involved

Baht 44.04 million

Baht 3.5881

No Dividend Payment

No AutoRedeem

1. Leverage Risk

2. The risk of changes in the price or value of the underlying asset.

3. Call Risk

4. Liquidity Risk

5 Business Bisk

6. Country Risk

7. Repatriation Risk

8. Market Risk

9. Credit Risk

10. Exchange rate Risk

11. Reinvestment Risk

12. The risk of delay payment from foreign funds.

Discretionary hedged

Health Care

20 August 2021


The Fund will invest in the investment unit of

Fund Performance vs Benchmark

ARK GENOMIC

72.49%

REVOLUTION ETF



Annual Return	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
SCBGENOME(A)	n.a.	-22.03%	-54.51%	6.04%						
Benchmark ¹	n.a.	-21.35%	-54.13%	10.36%						
Portfolio SD	n.a.	39.97%	59.51%	36.92%						
Benchmark SD	n.a.	40.19%	59.90%	35.68%						

Class Date 20 August 2021 **Fund Details**

Asset Allocation

Subscription / Redemption

Date & Time

FX hedging policy

AIMC Category

Before 3.30 p.m. of every working day and before 4.00 p.m. for SCB Easy

Minimum Additional Subcription

Amount

Minimum Redemption Baht 1,000 Minimum Balance Baht 1 000

Redemption Settlement Date

Baht 1,000 / Baht 1,000

4 business days after the date of redemption (T+4)

	/ 00111711
Security	
1.ARK GENOMIC REVOLUTION ETF	72.49
2.ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF	23.13
Industry	
1.UNIT TRUST	95.62

AIMC Category Performance Report

	Average Trailing Return (%)						Average Calendar Year Return (%)					
AIMC Category	YTD	3M	6M	1Y	3Y	5Y	10Y	2019	2020	2021	2022	2023
Health Care	3.48	11.13	3.76	5.32	-1.81	6.70	6.15	19.80	22.59	7.71	-19.54	-0.96

Fees Collected from Unit holders

Front-end fee

Back-end fee

Not exceed 3.21% of NAV (Currently charged at 1%) Not exceed 3.21% of NAV (waived)

Not exceed 3.21% of NAV

Switch In fee (Currently charged at 1%)

Switch Out fee Not exceed 3.21% of NAV (waived) **Brokerage Fee** Not exceed 0.75 % of NAV (waived)

(All Transaction)

Trustee Fee

Transfer fee Baht 10 per 1,000 units

Fees Collected from the Fund (included of VAT)(%p.a.of NAV)

Management Fee Not exceed 2.68 p.a. (Currently charged at 0.5%)

Not exceed 0.11 p.a.

(Currently charged at 0.0321%)

Not exceed 0.11 p.a. Registrar Fee

(Currently charged at 0.06955%)

Other expenses Actual expense Not exceed 2.68%

¹Performance of ARK Genomic Revolution ETF: 60% and performance of iShares Genomics Immunology and Healthcare ETF: 40% Adjusted with the cost of hedging the exchange rate to calculate the return in Thai baht on the investment date (50%) and adjust the exchange rate against the baht currency at the date of calculation of the return (50%).

